Hepatology

Top Story

Novel NASH treatment reduces hepatic fat, improves liver injury markers

April 22, 2017

AMSTERDAM — A pegylated form of the hormone FGF21 injected subcutaneously produced improvements in hepatic fat, fibrosis markers and metabolic parameters, according to data presented at the International Liver Congress.

“BMS-986036 10 mg daily and 20 mg weekly for 16 weeks, compared with placebo, significantly decreased hepatic fat fraction in patients with NASH and fibrosis 1 through 3,” Arun Sanyal, MD, from Virginia Commonwealth University, said during his late breaker presentation. “BMS-986036 daily and weekly — relative to placebo — was associated with improvements in biomarkers of fibrosis, metabolic parameters and markers of hepatic injury.”

Meeting News

Liver stiffness, controlled attenuation may predict decompensation

April 22, 2017
AMSTERDAM — Assessment of liver stiffness and controlled attenuation parameter may be useful as a novel predictor of decompensation, according to data presented at…
Meeting News

Nearly 80% respond to novel growth factor for NASH

April 22, 2017
AMSTERDAM — With 12 weeks of treatment, more than one-third of biopsy-diagnosed non-alcoholic steatohepatitis patients who received novel growth factor NGM282…
Meeting News

Ileal bile acid transporter inhibition promising for cholestatic liver disease

April 22, 2017
AMSTERDAM — A novel approach for cholestatic pruritus, ileal bile acid transporter inhibition, was associated with improvement in pruritus in nearly three-quarters…
Meeting News

Bezafibrate shows efficacy used in combination with UDCA for PBC

April 22, 2017
AMSTERDAM — Bezafibrate induced an additional biochemical response in patients with primary biliary cholangitis, improving pruritus and other markers, when used as…
More News Headlines »
CME

Rapid Response from Barcelona: New Data in HCV Treatment

This activity is supported by an educational grant from AbbVie and Merck & Co., Inc.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
GI Bookshelf

Question 43: Caroli's Disease, What Do I Need to Know?

From Curbside Consultation of the Pancreas: 49 Clinical Questions
More »
Featured
International Liver Congress

International Liver Congress

Video
Meeting News

VIDEO: Physician discusses distinct factors of NAFLD in pediatric patients

March 23, 2017
More »
Current Issues Current Issues
View the Current Issue
HCV Next
Advertisement
Advertisement